HER2

Scientific explanation

HER2/ERBB2 amplification or overexpression produces ligand-independent ERBB signalling, classically in a subset of breast and gastroesophageal cancers and rarely in colorectal cancer.

Cancers where relevant

Breast cancer HER2+ breast cancer Colorectal cancer HER2-amplified colorectal cancer Gastric cancer Esophageal cancer Cholangiocarcinoma

Compounds that intersect this pathway

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.